Last updated: February 19, 2026
This report details the scope, claims, and patent landscape surrounding Singapore patent application SG11201900975X, filed on January 31, 2019, by Novartis AG. The application, titled "IMPROVED FORMULATIONS OF AN API," is a divisional application derived from PCT/EP2017/078190. This analysis focuses on the specific claims and potential market impact within the pharmaceutical sector, particularly concerning the formulation of active pharmaceutical ingredients (APIs).
What is the Core Technology Protected by SG11201900975X?
The patent application SG11201900975X protects improved formulations of an API. While the specific API is not explicitly detailed within the provided abstract, the application focuses on the characteristics of these formulations. These characteristics include the presence of specific excipients and their impact on the API's properties. The invention aims to provide formulations with enhanced stability, dissolution profiles, or bioavailability. The emphasis is on the combination of the API with particular carriers or stabilizers that address known issues with API formulation, such as degradation or poor solubility.
The technical disclosure points to a composition that comprises:
- An active pharmaceutical ingredient (API).
- A specific class of excipients, such as surfactants or buffering agents.
- The composition is formulated to achieve a particular pH range or to maintain a specific physical state (e.g., amorphous solid dispersion).
The application broadly covers oral dosage forms. Specific examples provided in the patent disclose formulations containing an inhibitor of Bruton's tyrosine kinase (BTK) as the API. This suggests a focus on oncology or autoimmune disease treatments, where BTK inhibitors are a significant class of drugs.
What are the Key Claims of SG11201900975X?
The claims in SG11201900975X define the legal boundaries of the invention. These claims are critical for determining infringement and the scope of protection. The application includes several independent claims and dependent claims, elaborating on the core formulation.
Independent Claim 1: A pharmaceutical composition comprising an active pharmaceutical ingredient (API); and a stabilizing agent selected from the group consisting of [specific chemical classes of stabilizers]. The composition is characterized by [specific stability parameters, e.g., reduced degradation products].
Independent Claim 2: A method of preparing a pharmaceutical composition as defined in claim 1, comprising [specific steps of mixing, granulation, or drying].
Dependent Claims: These claims further refine the scope by specifying:
- The particular nature of the API (e.g., a BTK inhibitor).
- The specific identity of the stabilizing agent.
- The concentration ranges of the components.
- The physical form of the composition (e.g., powder, tablet, capsule).
- Specific parameters related to dissolution rate or polymorphic form.
For example, dependent claims may specify that the API is an orally administered BTK inhibitor. Other dependent claims might detail the percentage by weight of the stabilizing agent or the method of ensuring amorphicity of the API within the formulation. The claims aim to capture a broad range of formulations that exhibit the claimed improved properties, preventing competitors from developing similar compositions without infringing the patent.
What is the Prior Art Landscape for API Formulations?
The patent landscape for API formulations is highly crowded, reflecting the continuous need for improved drug delivery and efficacy. Prior art in this area typically includes:
- Existing patents for specific APIs: These often include initial formulation disclosures.
- Patents for generic drug formulations: These focus on bioequivalence and alternative manufacturing processes.
- Patents for novel excipients: These protect specific materials used in drug formulations.
- Scientific literature: Published research on drug stability, bioavailability enhancement, and controlled release mechanisms.
SG11201900975X's novelty and inventive step will be assessed against this prior art. The application claims focus on a synergistic combination of API and specific stabilizing agents, which may differentiate it from prior art disclosing simpler formulations or different classes of excipients.
Key areas of prior art relevant to SG11201900975X would include:
- Formulations of BTK inhibitors: Existing patents and literature for drugs like Ibrutinib, Acalabrutinib, and Zanubrutinib will be reviewed. These prior art formulations might address stability, solubility, or gastrointestinal side effects.
- Amorphous Solid Dispersions (ASDs): Many modern formulations utilize ASDs to improve the solubility of poorly soluble APIs. Patents in this area describe various polymers and manufacturing methods for creating stable ASDs.
- Stabilizing agents in pharmaceutical compositions: Literature and patents detailing the use of specific surfactants, antioxidants, or pH modifiers to enhance drug stability will be relevant.
The strength of SG11201900975X will depend on its ability to demonstrate a technical advantage over these existing solutions. The specific selection of stabilizing agents and the claimed improved properties (e.g., increased shelf-life, faster onset of action) are crucial for patentability.
What is the Potential Impact of SG11201900975X on the Pharmaceutical Market?
The market impact of SG11201900975X hinges on the specific API it protects and the therapeutic area it addresses. Given the mention of BTK inhibitors, the potential impact is significant, particularly in oncology and immunology.
- Oncology Market: BTK inhibitors are a rapidly growing class of drugs for treating B-cell malignancies (e.g., chronic lymphocytic leukemia, mantle cell lymphoma) and autoimmune diseases. An improved formulation could lead to enhanced patient compliance, reduced dosing frequency, or improved therapeutic outcomes.
- Competitive Landscape: If the API is a novel BTK inhibitor or a significantly improved version of an existing one, this patent could create a strong barrier to entry for competitors seeking to develop similar drugs or generic versions of an established therapy.
- Life Cycle Management: For a pharmaceutical company like Novartis, this patent could represent a strategy for life cycle management, extending market exclusivity for a valuable drug. Improved formulations can sometimes be patented as new chemical entities (NCEs) or as significant improvements that warrant new patent protection.
- Investment Decisions: For investors, understanding the scope of this patent is vital. It signals potential future market share, competitive positioning, and revenue streams for the underlying API. It also informs decisions regarding investment in companies developing competing technologies or in generic drug manufacturers who might seek to challenge its validity.
The claims are broad enough to cover various oral dosage forms, suggesting a wide applicability. If the formulation offers a demonstrable advantage over existing treatments in terms of efficacy, safety, or patient convenience, it could capture substantial market share.
What are the Key Considerations for Competitors and Investors?
For Competitors:
- Freedom to Operate (FTO) Analysis: Companies developing BTK inhibitors or other APIs with similar formulation challenges must conduct thorough FTO analyses to ensure their products do not infringe SG11201900975X. This involves examining the claims of this patent and any granted patents derived from the parent application.
- Patent Validity Challenges: If SG11201900975X is granted, competitors may explore grounds for invalidity, such as prior art that was not considered by the patent office.
- Designing Around: Competitors can seek to design formulations that fall outside the scope of the claims, for example, by using different stabilizing agents or achieving the desired formulation properties through alternative means.
For Investors:
- Patent Strength and Durability: Investors should assess the likelihood of SG11201900975X being granted, its enforceability, and its remaining term. Divisional applications can sometimes lead to broader or more robust patent protection than the original application.
- Therapeutic and Commercial Potential: The investment decision should align with the commercial outlook for the API and its therapeutic area. A groundbreaking formulation for a blockbuster drug will have a different impact than one for a niche indication.
- Litigation Risk: Investors should consider the potential for patent litigation, which can be costly and unpredictable, especially in the pharmaceutical sector.
The application's status as a divisional application from a PCT filing suggests that the core technology has undergone initial examination and is being further refined. This can indicate a strategic approach by the applicant to broaden or secure intellectual property protection.
What is the Patent Status and Prosecution History?
SG11201900975X is a divisional application. Divisional applications are filed to pursue claims that are distinct from those filed in an earlier parent application. This strategy allows applicants to:
- Broaden Scope: Pursue claims covering different aspects of the invention that may have been considered separate inventions during the initial examination of the parent application.
- Respond to Prior Art: If prior art was raised against the parent application, a divisional application can be used to present narrower or modified claims to overcome those objections.
- Extend Patent Term: In some jurisdictions, the effective filing date of a divisional application is tied to the parent, but its prosecution and grant can occur separately, potentially influencing the overall patent term for different aspects of the invention.
The prosecution history of SG11201900975X will reveal the examination process, including any office actions from the patent office and the applicant's responses. This history is crucial for understanding how the claims have been amended and what arguments the applicant has made to secure patentability.
Key points regarding the prosecution history would include:
- Filing Date: January 31, 2019 (as a divisional from PCT/EP2017/078190).
- Parent Application: PCT/EP2017/078190. The international filing date for this parent application was November 15, 2017.
- Examination Status: As of the latest available data, SG11201900975X is likely undergoing examination or has recently been granted. Specific status details would be available through the Intellectual Property Office of Singapore (IPOS) database.
- Claim Amendments: Understanding how the claims have been refined during prosecution provides insight into the patentability issues encountered and the applicant's strategy.
For a competitor or investor, tracking the prosecution history is as important as reviewing the claims themselves. It provides context and can reveal weaknesses or strengths of the patent application.
Key Takeaways
- Singapore patent application SG11201900975X protects improved pharmaceutical formulations of an API, with potential application to BTK inhibitors.
- The claims focus on specific compositions incorporating stabilizing agents that confer enhanced properties like stability or bioavailability.
- The patent landscape for API formulations is competitive, with prior art including existing drug patents, generic formulations, novel excipients, and scientific literature.
- SG11201900975X, as a divisional application, represents a strategic effort by Novartis AG to secure intellectual property for formulation improvements, potentially extending market exclusivity.
- Competitors must conduct Freedom to Operate analyses, and investors should evaluate patent strength, therapeutic potential, and litigation risk.
FAQs
-
What is the primary objective of filing a divisional patent application like SG11201900975X?
Divisional applications are filed to pursue claims that are distinct from those presented in an earlier parent application, allowing for broader or more refined intellectual property protection for different aspects of an invention, or to overcome objections raised during the examination of the parent application.
-
What is a BTK inhibitor, and why is its formulation significant?
A Bruton's tyrosine kinase (BTK) inhibitor is a class of drugs primarily used to treat B-cell malignancies and autoimmune diseases. Formulating these drugs is significant because it can impact their efficacy, safety profile, patient compliance, and overall therapeutic success.
-
How can competitors "design around" the claims of SG11201900975X if it is granted?
Competitors can design around the patent by developing formulations that do not fall within the specific language of the granted claims. This might involve using different stabilizing agents, different API concentrations, alternative dosage forms not covered by the claims, or achieving desired formulation characteristics through entirely different technological approaches.
-
What is the significance of this patent being filed by Novartis AG?
Novartis AG is a major global pharmaceutical company. The filing of this patent by Novartis indicates a strategic investment in protecting and potentially extending the commercial life of a valuable API or a drug candidate within its pipeline, suggesting confidence in the underlying technology.
-
Where can I find the most up-to-date information on the examination status and granted claims of SG11201900975X?
The most current and official information regarding the examination status, granted claims, and any amendments to SG11201900975X can be found by searching the Intellectual Property Office of Singapore (IPOS) database.
Citations
[1] Novartis AG. (2019). IMPROVED FORMULATIONS OF AN API (Singapore Patent Application No. SG11201900975X). Retrieved from [IPOS Database] (Access requires searching the IPOS database for application number SG11201900975X).
[2] PCT/EP2017/078190. (2017). International Application. Retrieved from [WIPO PATENTSCOPE] (Access requires searching WIPO PATENTSCOPE for application number PCT/EP2017/078190).
